A randomized placebo-controlled trial of bupropion for Cancer-related fatigue: Study design and procedures
Cancer-related fatigue is a significant problem and is associated with poor quality of life. Behavioral interventions include exercise and cognitive-behavioral therapy, which survivors may be unwilling or unable to adopt. Pharmacologic interventions (e.g., selective serotonin reuptake inhibitors) have been disappointing. One potential therapy is the antidepressant bupropion, a norepinephrine-dopamine reuptake inhibitor that targets both inflammation and the hypothalamic-pituitary-adrenal axis. The current study is intended to provide a rigorous test of the efficacy and tolerability of bupropion for cancer-related fatigue.
Source: Contemporary Clinical Trials - Category: Radiology Authors: Heather S.L. Jim, Aasha I. Hoogland, Hyo Sook Han, Eva Culakova, Charles Heckler, Michelle Janelsins, Geoffrey C. Williams, Julienne Bower, Stephen Cole, Zeruesenay Desta, Margarita Bobonis Babilonia, Gary Morrow, Luke Peppone Source Type: research
More News: Bupropion | Cancer | Cancer & Oncology | Clinical Trials | Radiology | Sports Medicine | Study | Wellbutrin